Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast03: Patritumab Deruxtecan + Pembrolizumab in Early-Stage Breast Cancer
NCT06797635Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of patritumab deruxtecan in breast cancer, sponsored by Merck & Co.. Started Mar 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06797635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06797635.